Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3733-3739

  Armand, Philippe ^a   Shipp, Margaret A ^b   Ribrag, Vincent ^c   Michot, Jean Marie ^d   Zinzani, Pier Luigi ^d   Kuruvilla, John ^e   Snyder, Ellen S ^e   Ricart, Alejandro D ^e   Balakumaran, Arun ^e   Rose, Shelonitda ^e   Moskowitz, Craig H ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BRENTUXIMAB VEDOTIN; GAMMA INTERFERON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; T LYMPHOCYTE RECEPTOR; ANTIBODY CONJUGATE; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AXILLARY PAIN; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CELL EXPANSION; CHILL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; COLITIS; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; JOINT SWELLING; MALE; NATURAL KILLER CELL; NAUSEA; NEPHROTIC SYNDROME; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; T LYMPHOCYTE; THYROIDITIS; TREATMENT FAILURE; VOMITING; XEROSIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HODGKIN DISEASE; METABOLISM; MIDDLE AGED; REMISSION; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; REMISSION INDUCTION; TREATMENT FAILURE; YOUNG ADULT;

EID: 84993993467     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.3467     Document Type: Conference Paper

References (24)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma. Version 2.2015. Fort Washington, PA, National Comprehensive Cancer Network Inc., 2015
2. Keir ME, Butte MJ, Freeman GJ, et al: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008
3. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
4. Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010
5. Green MR, Rodig S, Juszczynski P, et al: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 18:1611-1618, 2012
6. Brahmer JR, Tykodi SS, Chow LQM, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
7. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
8. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
9. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562, 2014
10. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
11. Armand P, Nagler A, Weller EA, et al: Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 31:4199-4206, 2013
12. Berger R, Rotem-Yehudar R, Slama G, et al: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044-3051, 2008
13. Westin JR, Chu F, Zhang M, et al: Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol 15:69-77, 2014
14. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
15. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
16. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events, version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
17. Seliger B, Ruiz-Cabello F, Garrido F: IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249-276, 2008
18. Agnello D, Lankford CS, Bream J, et al: Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. J Clin Immunol 23:147-161, 2003
19. Hu X, Chakravarty SD, Ivashkiv LB: Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 226: 41-56, 2008
20. Zaidi MR, Merlino G: The two faces of interferon-g in cancer. Clin Cancer Res 17:6118-6124, 2011
21. Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 33, 2015 (suppl; abstr 3001)
22. Puig N, Pintilie M, Seshadri T, et al: Different response to salvage chemotherapy but similar posttransplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica 95: 1496-1502, 2010
23. Seftel M, Rubinger M: The role of hematopoietic stem cell transplantation in advanced Hodgkin lymphoma. Transfus Apheresis Sci 37:49-56, 2007
24. Josting A, Engert A, Diehl V, et al: Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol 13(suppl 1):112-116, 2002